{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:41:10Z","timestamp":1792618870153,"version":"4.5.0"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computational Biology and Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.compbiolchem.2025.108663","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T23:24:24Z","timestamp":1756509864000},"page":"108663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"P1","title":["Structure-based drug design; Computational strategies in drug discovery; Antihypertensive agents; Antiviral drugs; Molecular docking; QSAR; Pharmacological insights"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0293-3491","authenticated-orcid":false,"given":"Asmaa M.","family":"Fahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2125.2003.01756.x","article-title":"Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers","volume":"55","author":"Aarnoutse","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib2","series-title":"Studies in Natural Products Chemistry","first-page":"197","article-title":"Chapter 6 - interactions between natural health products and antiretroviral drugs","author":"Abad Mart\u00ednez","year":"2014"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.136517","article-title":"Novel bis pyrimidine-pyrazolone and pyridinyl-4,5-dihydropyrimido[2,1[1]-c,1,2,4]triazepine utilized ultrasonic energy, anti-proliferative activity, docking simulation, and theoretical investigation","volume":"1294","author":"Aboelnaga","year":"2023","journal-title":"J. Mol. Struct."},{"issue":"4","key":"10.1016\/j.compbiolchem.2025.108663_bib4","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1538-7836.2007.02436.x","article-title":"A phase II study of the oral factor xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement","volume":"5","author":"Agnelli","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40409-015-0030-y","article-title":"Angiotensin-converting enzyme inhibitors of bothrops jararaca Snake venom affect the structure of mice seminiferous epithelium","volume":"21","author":"Alberto-Silva","year":"2015","journal-title":"J. Venom. Anim. Toxins Incl. Trop. Dis."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ncomms1390","article-title":"Mechanism of 150-cavity formation in influenza neuraminidase","volume":"2","author":"Amaro","year":"2011","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.compbiolchem.2025.108663_bib7","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1021\/jm800455g","article-title":"A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase","volume":"52","author":"An","year":"2009","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.compbiolchem.2025.108663_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chembiol.2003.09.002","article-title":"The process of structure-based drug design","volume":"10","author":"Anderson","year":"2003","journal-title":"J. Chem. Biol."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijmedinf.2019.02.005","article-title":"The effects of adverse drug reactions on patients\u2019 satisfaction: evidence from publicly available data on tamiflu (oseltamivir)","volume":"125","author":"Antipov","year":"2019","journal-title":"Int. J. Med. Inform."},{"issue":"5","key":"10.1016\/j.compbiolchem.2025.108663_bib10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003495-200565050-00005","article-title":"Amprenavir or fosamprenavir plus ritonavir in HIV infection","volume":"65","author":"Arvieux","year":"2005","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.compbiolchem.2025.108663_bib11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.compbiolchem.2025.108663_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0040-4039(00)75787-X","article-title":"Highly diastereoselective reaction of a chiral, non-racemic amide enolate with (S)-glycidyl tosylate. Synthesis of the orally active HIV-1 protease inhibitor L-735,524","volume":"35","author":"Askin","year":"1994","journal-title":"Tetrahedron Lett."},{"issue":"30","key":"10.1016\/j.compbiolchem.2025.108663_bib13","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1002\/ejoc.201900718","article-title":"Synthesis of chiral tetrahydrofuran building blocks from pantolactones: application in the synthesis of empagliflozin and amprenavir analogs","volume":"2019","author":"Athawale","year":"2019","journal-title":"Eur. J. Org. Chem."},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108663_bib14","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/j.jksus.2020.07.007","article-title":"Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme","volume":"32","author":"Bahadur Gurung","year":"2020","journal-title":"J. King Saud. Univ. Sci."},{"issue":"12","key":"10.1016\/j.compbiolchem.2025.108663_bib15","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1021\/jm00132a003","article-title":"Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma","volume":"32","author":"Baldwin","year":"1989","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.compbiolchem.2025.108663_bib16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2165\/00002512-199710050-00006","article-title":"Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension","volume":"10","author":"Balfour","year":"1997","journal-title":"Drugs Aging"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib17","doi-asserted-by":"crossref","unstructured":"Ballantyne, A.D. and C.M.J.D. Perry, Dolutegravir: first global approval. 2013. 73(14): p. 1627-1637, doi: 10.1007\/s40265-013-0121-4.","DOI":"10.1007\/s40265-013-0121-4"},{"issue":"12","key":"10.1016\/j.compbiolchem.2025.108663_bib18","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.cmi.2022.08.013","article-title":"European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild\/moderate disease","volume":"28","author":"Bartoletti","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135184","article-title":"Synthesis, antioxidant activity, docking simulation, and computational investigation of novel heterocyclic compounds and schiff bases from picric acid","volume":"1281","author":"Bayrak","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","article-title":"Predicting commercially available antiviral drugs that May act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","volume":"18","author":"Beck","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib21","unstructured":"Bowersox, J.J.N.Aa, Nevirapine approved by fda. food and drug administration. 1996: p. 10, \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/11363918\/\u3009."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40261-017-0492-5","article-title":"US FDA perspective on elbasvir\/grazoprevir treatment for patients with chronic hepatitis c virus genotype 1 or 4 infection","volume":"37","author":"Boyd","year":"2017","journal-title":"Clin. Drug Investig."},{"issue":"14","key":"10.1016\/j.compbiolchem.2025.108663_bib23","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1080\/00397919008053153","article-title":"A procedure for the preparation of pure 1,4-Cyclohexadiene from benzene","volume":"20","author":"Brandsma","year":"1990","journal-title":"Synth. Commun."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1039\/b208248a","article-title":"HIV-1 protease: mechanism and drug discovery","volume":"1","author":"Brik","year":"2003","journal-title":"J. Org. Biomol. Chem."},{"issue":"8","key":"10.1016\/j.compbiolchem.2025.108663_bib25","first-page":"608","article-title":"burger's medicinal chemistry and drug discovery","volume":"3","author":"Burger","year":"2003","journal-title":"Am. J. Ther."},{"issue":"11","key":"10.1016\/j.compbiolchem.2025.108663_bib26","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1021\/bi00735a008","article-title":"Binding of the by-product analog benzylsuccinic acid by carboxypeptidase a","volume":"12","author":"Byers","year":"1973","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.compbiolchem.2025.108663_bib27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.toxicon.2011.07.013","article-title":"Bradykinin-potentiating peptides: beyond captopril","volume":"59","author":"Camargo","year":"2012","journal-title":"Toxicon"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib28","series-title":"abacavir, in kucers' the use of antibiotics","first-page":"3773","author":"Cameron","year":"2017"},{"issue":"9","key":"10.1016\/j.compbiolchem.2025.108663_bib29","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/vaccines9090979","article-title":"Review of influenza virus vaccines: the qualitative nature of immune responses to infection and vaccination is a critical consideration","volume":"9","author":"Chan","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.V98.2.383","article-title":"The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals","volume":"98","author":"Chavan","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib31","doi-asserted-by":"crossref","first-page":"g2591","DOI":"10.1136\/bmj.g2591","article-title":"Oseltamivir: another case of regulatory failure?","volume":"348","author":"Cohen","year":"2014","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108663_bib32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1747-0285.2007.00599.x","article-title":"Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge","volume":"70","author":"Cohen","year":"2007","journal-title":"Chem. Biol. Drug Des."},{"issue":"25","key":"10.1016\/j.compbiolchem.2025.108663_bib33","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1021\/bi00644a014","article-title":"Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids","volume":"16","author":"Cushman","year":"1977","journal-title":"Biochemistry"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2019.115537","article-title":"Synthesis, anti-proliferative activity, computational studies of tetrazole cellulose utilizing different homogenous catalyst","volume":"229","author":"Dacrory","year":"2020","journal-title":"Carbohydr. Polym."},{"issue":"5","key":"10.1016\/j.compbiolchem.2025.108663_bib35","first-page":"1161","article-title":"Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin","volume":"21","author":"Dalva-Aydemir","year":"2015"},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00702-021-02306-2","article-title":"Amantadine: reappraisal of the timeless diamond\u2014target updates and novel therapeutic potentials","volume":"128","author":"Danysz","year":"2021","journal-title":"J. Neural Transm."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd703","article-title":"Strategies in the design of antiviral drugs","volume":"1","author":"De Clercq","year":"2002","journal-title":"J. Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcv.2004.02.009","article-title":"Antiviral drugs in current clinical use","volume":"30","author":"De Clercq","year":"2004","journal-title":"J. J. Clin. Virol."},{"issue":"3","key":"10.1016\/j.compbiolchem.2025.108663_bib39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib40","doi-asserted-by":"crossref","unstructured":"Deeks, E.D.J.D., Doravirine: first global approval. 2018. 78(15): p. 1643-1650, https:\/\/doi.org\/10.1007\/s40265-018-0993-4.","DOI":"10.1007\/s40265-018-0993-4"},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrd2512","article-title":"Fresh from the pipeline: raltegravir","volume":"7","author":"Deeks","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.compbiolchem.2025.108663_bib42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/bjo.86.4.378","article-title":"Periorbital dermatitis as a side effect of topical dorzolamide","volume":"86","author":"Delaney","year":"2002","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2005.07.003","article-title":"Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir","volume":"68","author":"Doyon","year":"2005","journal-title":"Antivir. Res."},{"issue":"01","key":"10.1016\/j.compbiolchem.2025.108663_bib44","first-page":"1","article-title":"Multidimensional QSAR modeling of amprenavir derivatives as HIV-Protease inhibitors","volume":"1","author":"Dubey","year":"2011","journal-title":"J. Open J. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib45","doi-asserted-by":"crossref","unstructured":"Eckhardt, B.J. and R.M. Gulick, 152 - Drugs for HIV Infection, in Infectious Diseases (Fourth Edition), J. Cohen, W.G. Powderly, and S.M. Opal, Editors. 2017, Elsevier. p. 1293-1308.e2.","DOI":"10.1016\/B978-0-7020-6285-8.00152-0"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib46","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review","volume":"12","author":"El Helou","year":"2019","journal-title":"Infect. Drug Resist"},{"issue":"9","key":"10.1016\/j.compbiolchem.2025.108663_bib47","first-page":"3204","article-title":"SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective","volume":"39","author":"Elfiky","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"5","key":"10.1016\/j.compbiolchem.2025.108663_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/13596535231199838","article-title":"Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach","volume":"28","author":"Elkaeed","year":"2023","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.143045","article-title":"Synthesis, theoretical investigation, and Anti-proliferative assessment of novel fused heterocyclic cellulosic derivatives in colorectal Caco-2 cells via suppressing the IL6\/STAT3 pathway","author":"Elsayed","year":"2025","journal-title":"J. Mol. Struct."},{"issue":"5","key":"10.1016\/j.compbiolchem.2025.108663_bib50","first-page":"559","article-title":"Maraviroc, risks and benefits: a review of the clinical literature","volume":"7","author":"Emmelkamp","year":"2008"},{"issue":"8","key":"10.1016\/j.compbiolchem.2025.108663_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jics.2024.101211","article-title":"Exploring novel benzene sulfonamide derivatives: synthesis, ADME studies, anti-proliferative activity, docking simulation, and emphasizing theoretical investigations","volume":"101","author":"Fahim","year":"2024","journal-title":"J. Indian Chem. Soc."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib52","doi-asserted-by":"crossref","first-page":"30566","DOI":"10.1038\/s41598-025-13192-z","article-title":"Properties and computational insights of catalysts based on amide linked polymer for photo-Fenton remediation of rhodamine b dye","volume":"15","author":"Fahim","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2019.127025","article-title":"Synthesis, antimicrobial evaluation, molecular docking and theoretical calculations of novel pyrazolo[1,5-a]pyrimidine derivatives","volume":"1199","author":"Fahim","year":"2020","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130660","article-title":"Enhancement of molecular imprinted polymer as organic fillers on bagasse cellulose fibers with biological evaluation and computational calculations","volume":"1241","author":"Fahim","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.molstruc.2019.04.078","article-title":"Microwave-assisted synthesis of novel 5-aminouracil-based compound with DFT calculations","volume":"1194","author":"Fahim","year":"2019","journal-title":"J. Mol. Struct."},{"issue":"9","key":"10.1016\/j.compbiolchem.2025.108663_bib56","first-page":"5707","article-title":"Numerous heterocyclic compounds with an isonicotinic moiety have been studied for their synthesis, antibacterial, anticancer, docking simulation, and DFT characteristics","volume":"44","author":"Fahim","year":"2024","journal-title":"Polycycl. Aromat. Compd."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140945","article-title":"Antimicrobial, antioxidant activities and ADME studies of novel BaSnO3 sulphone cellulose with docking simulation","volume":"1325","author":"Fahim","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"17","key":"10.1016\/j.compbiolchem.2025.108663_bib59","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r\u2013ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.compbiolchem.2025.108663_bib60","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/0002-8703(81)90233-7","article-title":"Clinical pharmacology and therapeutic applications of the new oral angiotensin converting enzyme inhibitor, captopril","volume":"101","author":"Ferguson","year":"1981","journal-title":"J. Am. Heart J."},{"issue":"13","key":"10.1016\/j.compbiolchem.2025.108663_bib61","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1021\/bi00815a005","article-title":"Isolation of bradykinin-potentiating peptides from bothrops jararaca venom","volume":"9","author":"Ferreira","year":"1970","journal-title":"Biochemistry"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib62","series-title":"xPharm: The Comprehensive Pharmacology Reference","first-page":"1","article-title":"Ritonavir","author":"Findlay","year":"2007"},{"issue":"4","key":"10.1016\/j.compbiolchem.2025.108663_bib63","first-page":"12","article-title":"Analogue-based drug discovery","volume":"32","author":"Fischer","year":"2010","journal-title":"J. Chem. Int. Newsmag. IUPAC"},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106708","article-title":"Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics","volume":"61","author":"Focosi","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"8","key":"10.1016\/j.compbiolchem.2025.108663_bib65","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1021\/jm00034a001","article-title":"Application of the Three-Dimensional structures of protein target molecules in Structure-Based drug design","volume":"37","author":"Greer","year":"1994","journal-title":"J. Med. Chem."},{"issue":"04","key":"10.1016\/j.compbiolchem.2025.108663_bib66","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1055\/s-0031-1290356","article-title":"Formal synthesis of tamiflu: conversion of tamiflu into tamiphosphor","volume":"2012","author":"Gunasekera","year":"2012","journal-title":"J. Synlett"},{"issue":"15","key":"10.1016\/j.compbiolchem.2025.108663_bib67","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1074\/jbc.M116.772996","article-title":"Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis c virus NS3\/4A protease from genotype 1a","volume":"292","author":"Guo","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib68","first-page":"99","article-title":"Tenofovir-associated fanconi syndrome: review of the FDA adverse event reporting system","volume":"22","author":"Gupta","year":"2008"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib69","doi-asserted-by":"crossref","unstructured":"Hamuy, R. and B.J.Do.T. Berman, Topical antiviral agents for herpes simplex virus infections. 1998. 34(12): p. 1013-1025, \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/9683881\/\u3009.","DOI":"10.1358\/dot.1998.34.12.487486"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib70","doi-asserted-by":"crossref","unstructured":"Hartman, G.D., et al., Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. 1992. 35(24): p. 4640-4642, \u3008https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/jm00102a020\u3009.","DOI":"10.1021\/jm00102a020"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.matchemphys.2023.128474","article-title":"Antimicrobial, antioxidant, mechanistic, docking simulation, and electrochemical studies for grafting polymerization of novel sulphonated gelatin derived from chicken feet","volume":"310","author":"Hashem","year":"2023","journal-title":"Mater. Chem. Phys."},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108663_bib72","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00003495-198020060-00001","article-title":"Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy","volume":"20","author":"Heel","year":"1980","journal-title":"Drugs"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib73","doi-asserted-by":"crossref","unstructured":"Hidalgo-Tenorio, C., et al., Bictegravir\/emtricitabine\/tenofovir alafenamide as first-line treatment in na\u00efve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial. 2024. 63(6): p. 107164, https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107164.","DOI":"10.1016\/j.ijantimicag.2024.107164"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib74","doi-asserted-by":"crossref","unstructured":"Hill, A., et al., Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. 2007. 8(5): p. 679-688, https:\/\/doi.org\/10.1517\/14656566.8.5.679.","DOI":"10.1517\/14656566.8.5.679"},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib75","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jac\/dkh357","article-title":"Lopinavir\/ritonavir combined with twice-daily 400\u2009mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen","volume":"54","author":"Isaac","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"issue":"25","key":"10.1016\/j.compbiolchem.2025.108663_bib76","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis c virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib77","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.idc.2022.01.006","article-title":"COVID-19 in the immunocompromised host, including people with human immunodeficiency virus","volume":"36","author":"Jakharia","year":"2022","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib78","first-page":"147","article-title":"Nelfinavir: a review of its therapeutic efficacy in HIV infection","volume":"56","author":"Jarvis","year":"1998"},{"issue":"8","key":"10.1016\/j.compbiolchem.2025.108663_bib79","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1002\/jmv.26990","article-title":"A brief review of influenza virus infection","volume":"93","author":"Javanian","year":"2021","journal-title":"J. Med Virol."},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib80","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.30840","article-title":"Pharmacokinetics, safety, and efficacy of Glecaprevir\/Pibrentasvir in adolescents with chronic hepatitis c virus: part 1 of the DORA study","volume":"71","author":"Jonas","year":"2020","journal-title":"Hepatology"},{"issue":"24","key":"10.1016\/j.compbiolchem.2025.108663_bib81","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1055\/s-2008-1077232","article-title":"Aliskiren","volume":"133","author":"Kappert","year":"2008","journal-title":"DMWDtsch. Med. Wochenschr."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib82","first-page":"1","article-title":"HSP90 inhibitors: current development and potential in cancer therapy","volume":"9","author":"Katerina","year":"2014","journal-title":"Recent Pat. AntiCancer Drug Discov."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib83","doi-asserted-by":"crossref","unstructured":"Katz, D.H., et al., Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. 1991. 88(23): p. 10825-10829, doi:10.1073\/pnas.88.23.10825.","DOI":"10.1073\/pnas.88.23.10825"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib84","doi-asserted-by":"crossref","DOI":"10.1177\/20587384211002621","article-title":"A review: mechanism of action of antiviral drugs","volume":"35","author":"Kausar","year":"2021","journal-title":"Int J. Immunopathol. Pharm."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib85","series-title":"Valganciclovir, a more potent oral therapy for CMV retinitis in AIDS, approved by FDA","author":"Kaye","year":"2001"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib86","doi-asserted-by":"crossref","unstructured":"Keating, G.M.J.D., Ombitasvir\/paritaprevir\/ritonavir: A review in chronic HCV genotype 4 infection. 2016. 76: p. 1203-1211, doi: 10.1007\/s40265-016-0612-1.","DOI":"10.1007\/s40265-016-0612-1"},{"issue":"4","key":"10.1016\/j.compbiolchem.2025.108663_bib87","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/jm970636+","article-title":"Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy","volume":"41","author":"Kempf","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.141480","article-title":"Unreported biginelli product with potent antifungal activity: synthesis, DFT insights, and docking simulation analysis","volume":"1330","author":"Kheder","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140586","article-title":"Synthesis, DFT investigation, molecular docking analysis, ADMET studies, and biological evaluation of a novel series of imidazolidinone derivatives as potential antimicrobial agents","volume":"1322","author":"Khodair","year":"2025","journal-title":"J. Mol. Struct."},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib90","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/md202073","article-title":"Drugs and cosmetics from the sea","volume":"2","author":"Kijjoa","year":"2004","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib91","doi-asserted-by":"crossref","unstructured":"Kim, C.U., et al., Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. 1997. 119(4): p. 681-690, \u3008https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/ja963036t\u3009.","DOI":"10.1021\/ja963036t"},{"issue":"3","key":"10.1016\/j.compbiolchem.2025.108663_bib92","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/ja00108a056","article-title":"Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme","volume":"117","author":"Kim","year":"1995","journal-title":"J. J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib93","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s42004-022-00758-5","article-title":"A sustainable synthesis of the SARS-CoV-2 mpro inhibitor nirmatrelvir, the active ingredient in paxlovid","volume":"5","author":"Kincaid","year":"2022","journal-title":"Commun. Chem."},{"issue":"18","key":"10.1016\/j.compbiolchem.2025.108663_bib94","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/acs.orglett.2c00944","article-title":"Environmentally responsible and Cost-Effective synthesis of the antimalarial drug pyronaridine","volume":"24","author":"Kincaid","year":"2022","journal-title":"Org. Lett."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib95","doi-asserted-by":"crossref","unstructured":"Kinch, M.S. and E.J.Ddt Patridge, An analysis of FDA-approved drugs for infectious disease: HIV\/AIDS drugs. 2014. 19(10): p. 1510-1513, doi: 10.1016\/j.drudis.2014.05.012.","DOI":"10.1016\/j.drudis.2014.05.012"},{"issue":"11","key":"10.1016\/j.compbiolchem.2025.108663_bib96","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nrd1549","article-title":"Docking and scoring in virtual screening for drug discovery: methods and applications","volume":"3","author":"Kitchen","year":"2004","journal-title":"J. Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108663_bib97","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1254\/fpj.115.323","article-title":"[Pharmacological profiles of the potent carbonic anhydrase inhibitor dorzolamide hydrochloride, a topical antiglaucoma agent]","volume":"115","author":"Kobayashi","year":"2000","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib98","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.eye.6700257","article-title":"The efficacy and safety of the timolol\/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma","volume":"17","author":"Konstas","year":"2003","journal-title":"Eye"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130092","article-title":"Synthesis of novel \u03b2-lactams: Antioxidant activity, acetylcholinesterase inhibition and computational studies","volume":"1233","author":"Fahim","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib100","doi-asserted-by":"crossref","unstructured":"Lamb, Y.N.J.D., Glecaprevir\/pibrentasvir: first global approval. 2017. 77: p. 1797-1804, doi: 10.1007\/s40265-017-0817-y.","DOI":"10.1007\/s40265-017-0817-y"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib101","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3762\/bjoc.12.267","article-title":"Computational methods in drug discovery","volume":"12","author":"Leelananda","year":"2016","journal-title":"Beilstein J. Org. Chem."},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108663_bib102","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bmcl.2005.12.020","article-title":"Acetylenic TACE inhibitors. Part 3: thiomorpholine sulfonamide hydroxamates","volume":"16","author":"Levin","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib103","unstructured":"Levinson, W., et al., Antiviral Drugs, in Review of Medical Microbiology & Immunology: A Guide to Clinical Infectious Diseases, 16e. 2020, McGraw Hill: New York, NY."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105555","article-title":"Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses","volume":"211","author":"Li","year":"2023","journal-title":"Antivir. Res"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib105","series-title":"Blum\u2013Ittah aziridine synthesis, in Name Reactions: A Collection of Detailed Mechanisms and Synthetic Applications","first-page":"52","author":"Li","year":"2009"},{"issue":"3","key":"10.1016\/j.compbiolchem.2025.108663_bib106","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cld.332","article-title":"Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment","volume":"3","author":"Lin","year":"2014","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"16","key":"10.1016\/j.compbiolchem.2025.108663_bib107","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2174\/1568026614666140929124445","article-title":"Structure-based virtual screening for drug discovery: principles, applications and recent advances","volume":"14","author":"Lionta","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib108","series-title":"Principles and Practice of Pediatric Infectious Disease","author":"Long","year":"2012"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114636","article-title":"The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins","volume":"162","author":"Loos","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.compbiolchem.2025.108663_bib110","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1440-1746.2008.05461.x","article-title":"Liver disease and the renin\u2013angiotensin system: recent discoveries and clinical implications","volume":"23","author":"Lubel","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108663_bib111","doi-asserted-by":"crossref","DOI":"10.1002\/aoc.70220","article-title":"The effect of anion, steric factors on the catalytic activity of hydrogen peroxide, biological activities, docking, and DFT calculations of novel mixed ligand of copper complexes","volume":"39","author":"Mahmoud","year":"2025","journal-title":"Appl. Organomet. Chem."},{"issue":"3","key":"10.1016\/j.compbiolchem.2025.108663_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.jics.2023.100891","article-title":"Computational investigation into Nirematrelvir\/Ritonavir synergetic efficiency compared with some approved antiviral drugs targeting main protease (Mpro) SARS-CoV-2 omicron variant","volume":"100","author":"Makhloufi","year":"2023","journal-title":"J. Indian Chem. Soc."},{"issue":"24","key":"10.1016\/j.compbiolchem.2025.108663_bib113","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.tet.2016.04.075","article-title":"Synthesis routes to anti-HIV drugs","volume":"72","author":"Mandala","year":"2016","journal-title":"Tetrahedron"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib114","doi-asserted-by":"crossref","unstructured":"Markham, A.J.D., Bictegravir: first global approval. 2018. 78: p. 601-606, https:\/\/doi.org\/10.1007\/s40265-018-0896-4.","DOI":"10.1007\/s40265-018-0896-4"},{"issue":"31","key":"10.1016\/j.compbiolchem.2025.108663_bib115","doi-asserted-by":"crossref","first-page":"28851","DOI":"10.1021\/acsomega.3c03959","article-title":"Stereoselective solvolysis in the synthesis of dorzolamide intermediates","volume":"8","author":"Martinelli","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib116","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","article-title":"The molecular biology of coronaviruses","volume":"66","author":"Masters","year":"2006","journal-title":"Adv. Virus Res"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib117","doi-asserted-by":"crossref","unstructured":"McCormack, P.L.J.D., Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection. 2015. 75: p. 515-524, https:\/\/doi.org\/10.1007\/s40265-015-0362-5.","DOI":"10.1007\/s40265-015-0362-5"},{"issue":"12","key":"10.1016\/j.compbiolchem.2025.108663_bib118","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1517\/14656566.2015.1066336","article-title":"Peramivir: an intravenous neuraminidase inhibitor","volume":"16","author":"McLaughlin","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.143269","article-title":"One-pot three-component synthesis, structural characterization, computational investigation, and anti-cancer evaluation of some novel benzo [g][1, 3, 5] oxadiazocine pyridine carboxamide hybrids","author":"Mohammed","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib120","doi-asserted-by":"crossref","unstructured":"Nagpal, P., et al., Long-range replica exchange molecular dynamics guided drug repurposing against tyrosine kinase PtkA of Mycobacterium tuberculosis. 2020. 10(1): p. 4413, https:\/\/doi.org\/10.1038\/s41598-020-61132-w.","DOI":"10.1038\/s41598-020-61132-w"},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib121","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/ph17010022","article-title":"Computer-aided drug design and drug discovery: a prospective analysis","volume":"17","author":"Niazi","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib122","article-title":"Computer-Aided drug design and drug discovery: a prospective analysis","volume":"17","author":"Niazi","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib123","doi-asserted-by":"crossref","unstructured":"O\u2019Hanlon, R. and M.L.J.Coiv Shaw, Baloxavir marboxil: the new influenza drug on the market. 2019. 35: p. 14-18, doi: 10.1016\/j.coviro.2019.01.006.","DOI":"10.1016\/j.coviro.2019.01.006"},{"issue":"20","key":"10.1016\/j.compbiolchem.2025.108663_bib124","doi-asserted-by":"crossref","first-page":"12149","DOI":"10.3390\/ijms232012149","article-title":"Discovery of novel HIV protease inhibitors using modern computational techniques","volume":"23","author":"Okafor","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4288","key":"10.1016\/j.compbiolchem.2025.108663_bib125","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1126\/science.191908","article-title":"Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents","volume":"196","author":"Ondetti","year":"1977","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108663_bib126","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/adt.2015.29011.tiodrrr","article-title":"Computational and practical aspects of drug repositioning","volume":"13","author":"Oprea","year":"2015","journal-title":"Assay. Drug Dev. Technol."},{"issue":"10","key":"10.1016\/j.compbiolchem.2025.108663_bib127","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1345\/aph.1D394","article-title":"Atazanavir","volume":"38","author":"Orrick","year":"2004","journal-title":"Ann. Pharmacother."},{"issue":"9","key":"10.1016\/j.compbiolchem.2025.108663_bib128","first-page":"1152","article-title":"Randomized double-blind trial of tromantadine versus aciclovir in recurrent herpes orofacialis","volume":"39","author":"Ostheimer","year":"1989","journal-title":"Arzneimittelforschung"},{"issue":"23","key":"10.1016\/j.compbiolchem.2025.108663_bib129","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5788","key":"10.1016\/j.compbiolchem.2025.108663_bib130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/288280a0","article-title":"A new class of angiotensin-converting enzyme inhibitors","volume":"288","author":"Patchett","year":"1980","journal-title":"J. Nat."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib131","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1007\/s00044-014-1072-3","article-title":"Quantitative structure\u2013activity relationship (QSAR) studies as strategic approach in drug discovery","volume":"23","author":"Patel","year":"2014","journal-title":"J. Med. Chem. Res."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib132","doi-asserted-by":"crossref","unstructured":"Perry, C.M. and D.J.D. Faulds, Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. 1997. 53: p. 657-680, doi: 10.2165\/00003495-199753040-00008.","DOI":"10.2165\/00003495-199753040-00008"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib133","doi-asserted-by":"crossref","unstructured":"Perry, C.M. and S.J.D. Noble, Didanosine: an updated review of its use in HIV infection. 1999. 58: p. 1099-1135, doi: 10.2165\/00003495-199958060-00009.","DOI":"10.2165\/00003495-199958060-00009"},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib134","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","article-title":"A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?","volume":"6","author":"Pilkington","year":"2020","journal-title":"J. Virus Erad."},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108663_bib135","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2165\/00003495-199958060-00011","article-title":"Indinavir: a review of its use in the management of HIV infection","volume":"58","author":"Plosker","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114217","article-title":"Natural products and synthetic analogues against HIV: a perspective to develop new potential anti-HIV drugs","volume":"233","author":"Popovi\u0107-Djordjevi\u0107","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.compbiolchem.2025.108663_bib137","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1134\/S1990750820030117","article-title":"Computer-aided drug design: from discovery of novel pharmaceutical agents to systems pharmacology","volume":"14","author":"Poroikov","year":"2020","journal-title":"Biochemistry (Moscow) Supplement Series B Biomedical Chemistry"},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib138","doi-asserted-by":"crossref","first-page":"30","DOI":"10.18097\/pbmc20206601030","article-title":"[Computer-aided drug design: from discovery of novel pharmaceutical agents to systems pharmacology]","volume":"66","author":"Poroikov","year":"2020","journal-title":"Biomed. Khim"},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib139","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib140","doi-asserted-by":"crossref","unstructured":"Qaqish, R.B., K.A. Mattes, and D.J.J.Ct Ritchie, Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. 2003. 25(12): p. 3084-3099, doi: 10.1016\/s0149-2918(03)90093-2.","DOI":"10.1016\/S0149-2918(03)90093-2"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2020.109808","article-title":"Current emerging SARS-CoV-2 pandemic: potential direct\/indirect negative impacts of virus persistence and related therapeutic drugs on the aquatic compartments","volume":"188","author":"Race","year":"2020","journal-title":"Environ. Res"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib142","doi-asserted-by":"crossref","unstructured":"Rajalakshmi, R., et al., Acyclovir versus valacyclovir. 2010. 76: p. 439,","DOI":"10.4103\/0378-6323.66577"},{"issue":"11","key":"10.1016\/j.compbiolchem.2025.108663_bib143","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1128\/AAC.48.11.4200-4208.2004","article-title":"Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 h compared with indinavir administered at 800 milligrams every 8 h in human immunodeficiency Virus-Infected patients","volume":"48","author":"Rhame Frank","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10223","key":"10.1016\/j.compbiolchem.2025.108663_bib144","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"lancet"},{"issue":"4","key":"10.1016\/j.compbiolchem.2025.108663_bib145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/1573406411006040247","article-title":"Oseltamivir: a first line defense against swine flu","volume":"6","author":"Ritesh","year":"2010","journal-title":"Med. Chem."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib146","doi-asserted-by":"crossref","unstructured":"Rittweger, M. and K.J.Cp Arast\u00e9h, Clinical pharmacokinetics of darunavir. 2007. 46: p. 739-756, doi: 10.2165\/00003088-200746090-00002.","DOI":"10.2165\/00003088-200746090-00002"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib147","doi-asserted-by":"crossref","unstructured":"Rivkin, A.J.Cmr and opinion, A review of entecavir in the treatment of chronic hepatitis B infection. 2005. 21(11): p. 1845-1856, https:\/\/doi.org\/10.1016\/j.clinthera.2006.02.012.","DOI":"10.1185\/030079905X65268"},{"issue":"51","key":"10.1016\/j.compbiolchem.2025.108663_bib148","doi-asserted-by":"crossref","first-page":"10085","DOI":"10.1016\/S0040-4039(00)01794-9","article-title":"A convergent synthesis approach towards CGP60536B, a non-peptide orally potent renin inhibitor, via an enantiomerically pure ketolactone intermediate","volume":"41","author":"R\u00fceger","year":"2000","journal-title":"Tetrahedron Lett."},{"issue":"7107","key":"10.1016\/j.compbiolchem.2025.108663_bib149","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature05114","article-title":"The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design","volume":"443","author":"Russell","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib150","doi-asserted-by":"crossref","unstructured":"Sanford, M.J.D., Simeprevir: a review of its use in patients with chronic hepatitis C virus infection. 2015. 75(2): p. 183-196, doi: 10.1007\/s40265-014-0341-2.","DOI":"10.1007\/s40265-014-0341-2"},{"issue":"9835","key":"10.1016\/j.compbiolchem.2025.108663_bib151","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib152","doi-asserted-by":"crossref","unstructured":"Schames, J.R., et al., Discovery of a novel binding trench in HIV integrase. 2004. 47(8): p. 1879-1881, \u3008https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/jm0341913\u3009.","DOI":"10.1021\/jm0341913"},{"issue":"15","key":"10.1016\/j.compbiolchem.2025.108663_bib153","doi-asserted-by":"crossref","first-page":"10464","DOI":"10.1039\/D4RA00602J","article-title":"Novel pyrazole and imidazolone compounds: synthesis, X-ray crystal structure with theoretical investigation of new pyrazole and imidazolone compounds anticipated insecticide\u2019s activities against targeting plodia interpunctella and nilaparvata lugens","volume":"14","author":"Shalaby","year":"2024","journal-title":"RSC Adv."},{"issue":"12","key":"10.1016\/j.compbiolchem.2025.108663_bib154","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","article-title":"ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease","volume":"42","author":"Sham","year":"1998","journal-title":"J. Antimicrob. Agents Chemother."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib155","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.biopha.2018.12.018","article-title":"Fiend and friend in the renin angiotensin system: an insight on acute kidney injury","volume":"110","author":"Sharma","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.tchem.2022.100033","article-title":"Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)","volume":"4","author":"Shekhar","year":"2022","journal-title":"Tetrahedron Chem."},{"issue":"9","key":"10.1016\/j.compbiolchem.2025.108663_bib157","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1248\/cpb.30.3139","article-title":"Synthesis of captopril starting from an optically active \u03b2-Hydroxy acid","volume":"30","author":"Shimazaki","year":"1982","journal-title":"Chem. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.compbiolchem.2025.108663_bib158","first-page":"545","article-title":"Mechanism of action of antiviral drugs","volume":"70","author":"Shiraki","year":"2012","journal-title":"J. Nihon rinsho. Jpn. J. Clin. Med."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib159","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/pr.112.007336","article-title":"Computational methods in drug discovery","volume":"66","author":"Sliwoski","year":"2014","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"10.1016\/j.compbiolchem.2025.108663_bib160","first-page":"483","article-title":"Antiviral drugs in the treatment of AIDS: what is in the pipeline ?","volume":"12","author":"Stellbrink","year":"2007","journal-title":"Eur. J. Med Res"},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib161","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/life12010116","article-title":"Ritonavir and xk263 Binding-Unbinding with HIV-1 protease: pathways, energy and comparison","volume":"12","author":"Sun","year":"2022","journal-title":"Life"},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib162","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"J. Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.compbiolchem.2025.108663_bib163","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11906-018-0823-9","article-title":"Dysregulation of the Renin-Angiotensin system and the vasopressinergic system interactions in cardiovascular disorders","volume":"20","author":"Szczepanska-Sadowska","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"issue":"8","key":"10.1016\/j.compbiolchem.2025.108663_bib164","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14787210.2022.2081153","article-title":"Cabotegravir\/Rilpivirine: the last FDA-approved drug to treat HIV","volume":"20","author":"Taki","year":"2022","journal-title":"Expert Rev. AntiInfect. Ther."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib165","doi-asserted-by":"crossref","unstructured":"Talele, T.T., S.A. Khedkar, and A.C.J.Ctimc Rigby, Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. 2010. 10(1): p. 127-141, https:\/\/doi.org\/10.2174\/156802610790232251.","DOI":"10.2174\/156802610790232251"},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib166","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/jm500480k","article-title":"Discovery of type II inhibitors of TGF\u03b2-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)","volume":"58","author":"Tan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140795","article-title":"New mercaptopyrimidine derivatives synthesized with expected antimicrobial and antioxidant properties and theoretical study","volume":"1324","author":"Tolan","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib168","doi-asserted-by":"crossref","unstructured":"Tompa, D.R., et al., Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. 2021. 172: p. 524-541, https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.01.076.","DOI":"10.1016\/j.ijbiomac.2021.01.076"},{"issue":"4","key":"10.1016\/j.compbiolchem.2025.108663_bib169","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1517\/14656566.2015.1012493","article-title":"Dasabuvir: a new direct antiviral agent for the treatment of hepatitis c","volume":"16","author":"Trivella","year":"2015","journal-title":"Expert Opin. Pharm."},{"issue":"3","key":"10.1016\/j.compbiolchem.2025.108663_bib170","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/jpids\/pit048","article-title":"Ganciclovir, Foscarnet, and Cidofovir: Antiviral Drugs Not Just for Cytomegalovirus","volume":"2","author":"Upadhyayula","year":"2013","journal-title":"J. Pediatr. Infect. Dis. Soc"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib171","doi-asserted-by":"crossref","unstructured":"Van Drie, J.H.J.Joc-amd, Computer-aided drug design: the next 20 years. 2007. 21(10): p. 591-601, https:\/\/doi.org\/10.1007\/s10822-007-9142-y.","DOI":"10.1007\/s10822-007-9142-y"},{"issue":"3","key":"10.1016\/j.compbiolchem.2025.108663_bib172","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.pharmthera.2009.07.004","article-title":"Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness","volume":"124","author":"Vergara-Rodriguez","year":"2009","journal-title":"J. Pharmacol. Ther."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib173","doi-asserted-by":"crossref","unstructured":"Vijayakrishnan, R.J.Jopm, Structure-based drug design and modern medicine. 2009. 55(4): p. 301-304, DOI: 10.4103\/0022-3859.58943.","DOI":"10.4103\/0022-3859.58943"},{"issue":"4","key":"10.1016\/j.compbiolchem.2025.108663_bib174","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1128\/AAC.00854-06","article-title":"Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a Twice-Daily boosted Double-Protease inhibitor regimen","volume":"51","author":"von Hentig","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.compbiolchem.2025.108663_bib175","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1080\/07391102.2020.1747550","article-title":"An effective molecular blocker of ion channel of M2 protein as anti-influenza a drug","volume":"39","author":"Vorobjev","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108663_bib176","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14656566.8.6.851","article-title":"Efavirenz: a review","volume":"8","author":"Vrouenraets","year":"2007","journal-title":"J. Expert Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib177","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/med.21728","article-title":"COVID-19 drug repurposing: a review of computational screening methods, clinical trials, and protein interaction assays","volume":"41","author":"Wang","year":"2021","journal-title":"Med Res Rev."},{"key":"10.1016\/j.compbiolchem.2025.108663_bib178","article-title":"A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide","volume":"19","author":"Wassner","year":"2020","journal-title":"J. Int. Assoc. Provid. AIDS Care (JIAPAC)"},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib179","article-title":"Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis","volume":"1","author":"Wilhelmus","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108663_bib180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003088-200645020-00002","article-title":"Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug","volume":"45","author":"Wire","year":"2006","journal-title":"Clin. Pharm."},{"issue":"11","key":"10.1016\/j.compbiolchem.2025.108663_bib181","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2533\/chimia.1996.532","article-title":"Synthesis of the HIV-Proteinase inhibitor saquinavir: a challenge for process research","volume":"50","author":"Wolfgang G\u00f6hring","year":"1996","journal-title":"CHIMIA"},{"issue":"10359","key":"10.1016\/j.compbiolchem.2025.108663_bib182","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"Wong","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.compbiolchem.2025.108663_bib183","article-title":"Oseltamivir phosphate loaded pegylated-Eudragit nanoparticles for lung cancer therapy: characterization, prolonged release, cytotoxicity profile, apoptosis pathways and in vivo anti-angiogenic effect by using CAM assay","volume":"139","author":"Yurtda\u015f-K\u0131r\u0131ml\u0131o\u011flu","year":"2022","journal-title":"Micro Res"},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108663_bib184","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov."}],"container-title":["Computational Biology and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147692712500324X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147692712500324X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T22:09:03Z","timestamp":1765922943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147692712500324X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":184,"alternative-id":["S147692712500324X"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2025.108663","relation":{},"ISSN":["1476-9271"],"issn-type":[{"value":"1476-9271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based drug design; Computational strategies in drug discovery; Antihypertensive agents; Antiviral drugs; Molecular docking; QSAR; Pharmacological insights","name":"articletitle","label":"Article Title"},{"value":"Computational Biology and Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2025.108663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108663"}}